H. Ralph Schumacher, Jr., MD, has a zest for research
Search results for: heart
Drug Updates: Information on New Approvals and Medication Safety
Information on New Approvals and Medication Safety
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Don’t Get Lost in Translation: Helping rheumatology Patients with Limited English Skills
Helping rheumatology patients with limited English skills
Coding Corner Question
December’s Coding Challenge
PAC Progress and Challenges
After three years, RheumPAC has a solid start, and more work ahead of it
Coding Corner Question
November’s Coding Challenge
Within Our Reach–Funded Research May Hold Key to Unlocking the CNS and Suppressing RA
Studies recently published in Arthritis & Rheumatism show that a key chemical produced by the central nervous system (CNS) decreases inflammation and suppresses production of proteins known to play a role in rheumatoid arthritis (RA). This opens the way for developing a novel class of drugs that mimic this effect of the CNS on RA.
Pharmaceutical Tourism
Could trade agreements and not bulky legislation be the key to cheaper drugs?
The Canes of York
What can a walking stick tell us about U.S. healthcare?
- « Previous Page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- …
- 96
- Next Page »